BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.17 Average PT from Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $15.17.

A number of brokerages have weighed in on BCRX. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays lifted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Finally, Needham & Company LLC increased their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, January 13th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Counterweight Ventures LLC raised its position in BioCryst Pharmaceuticals by 591.7% in the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company's stock worth $710,000 after buying an additional 79,884 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of BioCryst Pharmaceuticals by 40.7% in the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock worth $2,274,000 after acquiring an additional 86,571 shares during the period. Principal Financial Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after purchasing an additional 375,890 shares during the last quarter. Rice Hall James & Associates LLC lifted its position in BioCryst Pharmaceuticals by 4.0% during the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock valued at $16,444,000 after purchasing an additional 84,102 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after purchasing an additional 481,359 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ:BCRX traded up $0.11 during trading on Thursday, hitting $7.73. The stock had a trading volume of 2,857,432 shares, compared to its average volume of 2,608,631. The company has a market capitalization of $1.60 billion, a PE ratio of -12.67 and a beta of 1.76. The firm's fifty day moving average is $7.56 and its 200 day moving average is $7.64. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. The business's quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.19) EPS. Equities research analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.